Fananserin

Nowadays, Fananserin is a topic on everyone's lips. Whether due to its relevance in the social sphere, its impact on the economy or its influence on popular culture, Fananserin has captured the attention of a large number of people around the world. This phenomenon is not surprising, as Fananserin possesses a number of characteristics that make it worthy of study and interest by academics, experts, and enthusiasts alike. In this article, we will explore in depth some of the most prominent facets of Fananserin, analyzing its importance today and its potential impact in the future. Through a rigorous and exhaustive analysis, we will seek to shed light on this highly relevant topic and offer a comprehensive vision that allows readers to better understand its scope and significance.

Fananserin
Clinical data
Other namesFananserin
ATC code
  • none
Identifiers
  • 2-(3-(4-(p-Fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H24FN3O2S
Molar mass425.52 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCCN2C3=CC=CC4=C3C(=CC=C4)S2(=O)=O)C5=CC=C(C=C5)F
  • InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2 ☒N
  • Key:VGIGHGMPMUCLIQ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Fananserin (RP-62203) is a drug which acts as a potent antagonist at both the 5HT2A receptor,[1] and the Dopamine D4 receptor,[2] but without blocking other dopamine receptors such as D2.[3] It has sedative[4] and antipsychotic effects, and has been researched for the treatment of schizophrenia,[5] although efficacy was less than expected and results were disappointing.[6]

References

  1. ^ Malleron JL, Comte MT, Gueremy C, Peyronel JF, Truchon A, Blanchard JC, et al. (August 1991). "Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonists". Journal of Medicinal Chemistry. 34 (8): 2477–83. doi:10.1021/jm00112a025. PMID 1908521.
  2. ^ Heuillet E, Petitet F, Mignani S, Malleron JL, Lavayre J, Néliat G, et al. (October 1996). "The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor". European Journal of Pharmacology. 314 (1–2): 229–33. doi:10.1016/s0014-2999(96)00554-7. PMID 8957240.
  3. ^ Doble A, Girdlestone D, Piot O, Allam D, Betschart J, Boireau A, et al. (January 1992). "Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist". British Journal of Pharmacology. 105 (1): 27–36. doi:10.1111/j.1476-5381.1992.tb14206.x. PMC 1908636. PMID 1596688.
  4. ^ Stutzmann JM, Eon B, Lucas M, Blanchard JC, Laduron PM (April 1992). "RP 62203, a 5-hydroxytryptamine2 antagonist, enhances deep NREM sleep in rats". Sleep. 15 (2): 119–24. doi:10.1093/sleep/15.2.119. PMID 1579785.
  5. ^ Sramek JJ, Kirkesseli S, Paccaly-Moulin A, Davidson J, Jhee SS, Hourani J, et al. (1998). "A bridging study of fananserin in schizophrenic patients". Psychopharmacology Bulletin. 34 (4): 811–8. PMID 10513457.
  6. ^ Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Rivière ME, Papillon-Downey C (March 1999). "Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia". The American Journal of Psychiatry. 156 (3): 419–25. doi:10.1176/ajp.156.3.419. PMID 10080558. S2CID 41422352.